<DOC>
	<DOCNO>NCT02480608</DOCNO>
	<brief_summary>The study test tolerability efficacy combination therapy Imatinib/Hydroxyurea ( HU ) patient chronic myeloid leukemia ( CML ) first chronic phase ( CP1 ) newly diagnosted fail interferon-based therapy .</brief_summary>
	<brief_title>Treatment CML Patients With Imatinib Hydroxyurea ( CML2004 )</brief_title>
	<detailed_description>The protocol consist part 1 , phase I study enrol 20 patient , goal determine safety combination well maximal tolerate dose . If toxicity combination acceptable , 200 patient may recruit randomized receive either Imatinib/HU Imatinib alone ( part 2 ) . Patients meet inclusion criterion start 400 mg Imatinib daily . In part 1 protocol , dose HU increase 500 mg 3-weekly interval maximal tolerate dose reach . In part 2 study , patient randomize receive either combination Imatinib monotherapy . Hematological cytogenetic response evaluate 3-months interval first year , 6 month ' interval thereafter . Primary endpoint part 1 dose-limiting toxicity maximal tolerate dose . Primary endpoint part 2 rate major complete molecular response 6 , 12 18 month , respectively .</detailed_description>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Phpositive CML CP1 , newly diagnose resistant ( hematologic cytogenetic ) intolerant interferonbased therapy 2 . Age ≥ 18 year 3 . Negative pregnancy test 4 . Low intermediate risk patient young 45 HLA ( Human Leukocyte Antigen ) match sibling donor medically fit undergo allografting include adequately counsel potential risk ( disease progression ) associate delay allograft 5 . Informed consent 1 . Objective sign disease progression beyond CP1 define bone marrow peripheral blood blast &gt; 15 % and/or blast + promyelocytes ≥ 30 % and/or peripheral blood basophil ≥ 20 % and/or platelet &lt; 100/nl and/or chromosomal abnormality addition Ph chromosome 2 . Findings suggestive extramedullary involvement 3 . Any severe uncontrolled medical condition 4 . Previous treatment Imatinib ( part 2 study ) 5 . History noncompliance 6 . Simultaneous inclusion study Important note : previous treatment Imatinib exclusion criterion part 1 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>